Vicapsys Life Sciences, Inc.

As of September 30, 2024, Vicapsys Life Sciences, Inc. carries a market capitalization of 48.88M, placing it among publicly traded companies globally. Its enterprise value stands at 49.37M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of September 30, 2024, Vicapsys Life Sciences, Inc. has 32.37M shares outstanding.

These figures are as of September 30, 2024.

As of September 30, 2024, Vicapsys Life Sciences, Inc. maintains a current ratio of 0.03, meaning it holds 0.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -21.88, indicating conservative leverage, while an interest coverage ratio of -12.26 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended September 30, 2024. Return on assets (ROA) is negative at -904.18, reflecting losses generated across the asset base. The company generates approximately - - in revenue per employee across its workforce of 2.00, a quick read on workforce productivity versus industry peers.

As of the close on October 22, 2026, Vicapsys Life Sciences, Inc.'s stock has declined approximately 77.40% over the past 52 weeks. The 50-day moving average sits at 1.82, while the 200-day moving average is 2.02.

Over the twelve months ended September 30, 2024, Vicapsys Life Sciences, Inc. generated - - in revenue and converted that into -1.35M in net income, yielding earnings per share of -0.04. EBITDA reached -1.11M, while operating income came in at -1.11M.

As of September 30, 2024, Vicapsys Life Sciences, Inc. holds 89,569.00 in cash and equivalents against 578,949.00 in total debt, resulting in a net debt position of 489,380.00. Total book value stands at -2.65M, with working capital of -2.65M providing operational flexibility.

Vicapsys Life Sciences, Inc. produced -125,741.00 in operating cash flow over the twelve months ended September 30, 2024.

These figures cover the twelve months ended September 30, 2024. Free cash flow yield is negative at -0.25: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow.

Vicapsys Life Sciences, Inc.'s most recent stock split took place on November 3, 2017 with a 100:1 split ratio.

As of September 30, 2024, Vicapsys Life Sciences, Inc. has an Altman Z-Score of -332.24, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.